Connor, Clark & Lunn Investment Management (CC&L)’s Tango Therapeutics TNGX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.43M	Buy	355,229 +225,753	+174%	+$3.14M	0.02%	564
2025 Q4	$1.15M	Buy	+129,476	New	+$1.12M	﹤0.01%	1091
2024 Q2	–	Sell	-196,384	Closed	-$1.56M	–	1694
2024 Q1	$1.56M	Buy	196,384 +15,786	+9%	+$169K	0.01%	744
2023 Q4	$1.79M	Buy	180,598 +161,177	+830%	+$1.4M	0.01%	698
2023 Q3	$219K	Buy	19,421 +7,077	+57%	+$43.2K	﹤0.01%	1222
2023 Q2	$41K	Buy	+12,344	New	+$44.4K	﹤0.01%	1276

Other funds holding TNGX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TNGX Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Tango Therapeutics (TNGX) stake by 174% in Q1 2026, buying an estimated $3.14M and bringing the position to 355,229 shares worth $7.43M. The position accounts for 0.02% of the portfolio, ranked #564.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in TNGX in Q2 2023 and has held it in 6 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 355,229 shares of Tango Therapeutics worth $7.43M as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 225,753 Tango Therapeutics shares in Q1 2026, an estimated $3.14M.
Tango Therapeutics made up 0.02% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #564 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Tango Therapeutics in Q2 2023 and has held it in 6 quarters since.
194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.